TherVacB
Phase 2Biologic
TherVacB is one of 35 biologic programs targeting Hepatitis B. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
44 competitors in Hepatitis B
#DrugCompanyPhaseTrials
1Vemlidy
GileadApproved
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Emtriva
GileadApproved
Selzentry
GSKApproved
Epivir
GGlaxo Dba Glaxosmithkline
Approved
Sunlenca
GileadApproved
Cabenuva
GSKApproved
Sustiva
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Retrovir
BBp Consulting, Inc
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TherVacB. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- MMichael Hoelscher